Vaccines and Global Health: The Week in Review
19 November 2022 :: Issue 680
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
**Milestones, Perspectives**

G20 hosts Official Launch of The Pandemic Fund

BALI, November 13, 2022 — The G20 Presidency of Indonesia, in partnership with the Pandemic Fund secretariat, today officially launched the Pandemic Fund at a high-level event, opened by Joko Widodo, President of Indonesia, on the margins of the G20 Joint Finance and Health Ministers’ Meeting.

...Drawing on lessons from COVID-19, which exposed huge weaknesses and underinvestment in pandemic prevention, preparedness and response (PPR), particularly in low- and middle-income countries, the Pandemic Fund is intended to strengthen the capacity of these countries to mitigate the risks of future global health threats. It will provide a dedicated stream of long-term financing for PPR and address critical gaps through investments and technical support at the national, regional, and global levels. The Pandemic Fund is also expected to incentivize countries to prioritize this agenda and increase their own efforts.

“This is the first time the international community has come together around a funding mechanism dedicated to investing in pandemic prevention, preparedness, and response in developing countries - a testament to multilateralism, said Dr. Chatib Basri, co-Chair of the Pandemic Fund Governing Board.

“The Pandemic Fund has a unique and vital role to play in making the world safer. PPR is a global public good that benefits all. Every dollar we mobilize to invest in PPR now in low- and middle-income countries will save lives and financial costs and lead to a more resilient world for years to come.”

Developed with Indonesia’s and Italy’s leadership during their respective G20 presidencies, the Pandemic Fund has US$1.4 billion in seed funding already committed by 24 donors. The World Bank and WHO engaged with a wide range of stakeholders including partner countries, civil society organizations (CSOs), and potential implementing entities to create the Pandemic Fund.

“The Pandemic Fund’s structure provides a firm footing for successful operationalization”, said Priya Basu, Executive Head of the Pandemic Fund Secretariat. “Its inclusive governance balances representation from contributors and co-investors, and provides a strong voice for civil society. We’ve built flexibility to deliver support to countries through a variety of existing institutions engaged in international financing of PPR, complementing their work and what countries themselves are doing. We’re focused on fostering coordination among partners and will maintain high standards of transparency and accountability. ”

Since the Pandemic Fund’s establishment in September with the first meeting of its Governing Board, much has been achieved across multiple workstreams. This includes progress in defining principles, priorities, and criteria for allocating funds so as to achieve the highest impact, and in forming the Technical Advisory Panel (TAP) in preparation for the first call for proposal expected in mid December 2022 or early January 2023.

The TAP, under the leadership of its new Chair Dr Michael Ryan, will assess and make recommendations to the Governing Board on the technical merits of proposals for funding, ensuring
linkages to the International Health Regulations (2005) and other internationally endorsed legal frameworks, consistent with a One Health approach, as part of the broader global PPR architecture.

The Pandemic Fund

The Pandemic Fund is a collaborative partnership among donor countries, co-investor countries (potential implementing country governments), foundations and civil society organizations (CSOs). It is hosted by the World Bank with WHO as technical lead.

The governing and administrative bodies of The Pandemic Fund are the Governing Board, the Technical Advisory Panel (TAP), the Secretariat, and the Trustee. The Implementing Entities (IEs) will support implementation of The Pandemic Fund-financed projects and activities. A broad set of stakeholders, including donors, Civil Society Organizations (CSOs), potential implementing country governments, and other partners were engaged on the The Pandemic Fund’s design to ensure it reflected the fund’s commitment to inclusivity, equity and to operate with high standards of transparency and accountability...

Remarks by World Bank Group President David Malpass at the G20 Launch Event for the Pandemic Fund in Bali, Indonesia
Date: November 13, 2022 Type: Statement
This new, dedicated Fund is an important tool that will support low- and middle-income countries and regions to become better prepared for global health crises. Moreover, we expect it will incentivize countries to prioritize this agenda and increase their own efforts.

I thank the founding donors for their leadership and generous seed contributions. I am encouraged that over $1.4 billion has already been committed by 24 donors, and I understand that additional pledges are forthcoming. I urge all countries to contribute to the Fund.

The Pandemic Fund is a testament to the possibility of global coordination. The Fund was championed by Italy and Indonesia during their respective G20 presidencies. The World Bank was pleased to support these efforts and help build consensus through evidence-based analysis and lessons from good practice and many years of experience.

Together with our G20 partners, the founding donors, WHO, Civil Society Organizations, and other stakeholders, we were able to develop the Fund at record speed. We are pleased to host the Secretariat and to serve as the Fund’s Trustee and as an Implementing Entity.

Through dedicated investments in pandemic prevention, preparedness, and response, the Pandemic Fund can help make the world safer. Its very nature contributes to a global public good, with benefits that are shared by all, across borders. Every dollar we mobilize for the Fund that can be invested now in low- and middle-income countries will save lives and reduce costs for the world for years to come.

I’m happy that the Pandemic Fund’s governance and operational structure is grounded in the spirit of shared responsibilities that need to address global public goods:
- First, the Fund’s governance is agile and inclusive, by representing contributors, co-investors, and civil society.
- Second, the operating structure is flexible to deliver support to countries and regions through existing institutions and, therefore, complements their work and draws on their comparative advantages.
- And third, the Fund’s structure incorporates high standards of transparency and accountability.

The health, economic, and social ripple effects of COVID-19 are a stark reminder that preparedness is vital. We’ve seen millions of lives lost and severe reversals in development. We cannot afford to let this happen again.

The Pandemic Fund provides an opportunity to do things differently by helping countries, regions, and the world be stronger in the face of global threats...

Beyond the COVID-19 Emergency :: Sustaining and Expanding Vaccine Equity
20 Recommendations from Public Health and Equity Leaders
Supported by The Rockefeller Foundation, Brown University School of Public Health, Equity-First Vaccination Initiative
2022 :: 13 pages
In this statement, members of the Rockefeller Foundation’s Equity Advisory Council – a group of 13 public health and equity experts representing diverse communities – call on government authorities and
Congress to make available the funding, technical expertise and political support required to make the recent progress on vaccine equity a permanent feature of the new normal.

The Council provides 20 evidence-based recommendations that grew out of the basic understanding that vaccine equity starts at the community level, and that efforts to build vaccine confidence and demand need to be prioritized as much as efforts to create vaccine supply. To do this, federal, state and local governments need to invest in communities and CBOs for sustained engagement, ensure community leaders are included as leaders and designers in initiatives, support equity-centered data collection, and build communications teams that include community leaders who can consistently adapt messages to meet local cultures and needs. Federal officials also need to do a better job of acknowledging uncertainty, telling stories, and using visuals.

The Council’s recommendations, alongside other in-depth readouts from the Rockefeller Foundation’s Equity-First Vaccination Initiative, serve as a roadmap for how to consistently build vaccine and health equity into public health, healthcare and civic society responses broadly – and why we must do so.

**At a Glance: 20 Action-Steps to Ensuring Vaccine Equity**

**Community Leadership**
1. Engage diverse community representatives in policy making and rollout
2. Ensure community members are leaders and designers at all points of initiatives

**Trust Building**
3. Build a collaborative communications infrastructure
4. Build misinformation resilience with trusted messengers and trusted community organizations at the center

**Access**
5. Bring vaccines to wherever people are and work with existing community infrastructure
6. Unlock funding and other support
7. Designate community workers as “essential workers”
8. Build for the long term

**Capacity Building**
9. Invest in communities and CBOs for sustained engagement
10. Build, sustain, and entrench public health capacity over the long term
11. Combine support for evaluation of community work with trust

**Data Availability**
12. Support equity-centered data collection
13. Publish and share public health data
14. Fund data infrastructure modernization for health settings at the federal, state and local levels
15. Ensure timely and high-quality data is accessible to various stakeholders across the health system, including community members

**Effective Governance**
16. Activate diverse funding streams tailored to the needs of community-based organizations
17. Co-creating with community organizations also means understanding their funding needs
18. Advocate for political leaders to highlight needs of vulnerable groups

**Healthcare, Public Health and Community Readiness**
19. Clinical research and trials must reach communities of color
20. Leverage trusted health workers
Public Health and Equity Leaders Release Recommendations for Expanding Covid-19 Vaccine Equity

The Rockefeller Foundation Equity Advisory Council outlines 20 actions to support vaccine and health equity in transition from response to recovery

NEW YORK | November 14, 2022 – A panel of leading experts on vaccine equity is urging federal, state, and local authorities to sustain and expand the significant progress that has been made to ensure equitable access to Covid-19 vaccinations. The 20 recommendations include the formal designation and inclusion of community-based organizations and workers (CBOs/CBW) as essential members of the public health infrastructure. If implemented, these recommendations can help save lives in vulnerable communities hit hard by the pandemic and ensure communities are ready to respond to future outbreaks.

“Community health workers have been on the front lines of this pandemic, and yet too often they’ve been an afterthought in the public health community,” said Denise Smith, Equity Advisory Council Member and Executive Director of the National Association of Community Health Workers. “If we want to eliminate racial disparities in public health, we need to designate community health workers as trusted and critical infrastructure workers, just like other healthcare personnel who are on the front lines during emergencies like the Covid-19 pandemic.”

The Rockefeller Foundation Equity Advisory Council, a 13-member panel of public health and equity experts representing diverse communities, noted that only a small portion of CBOs that worked on access to and confidence in testing, vaccines, and treatments during the pandemic are considered part of traditional healthcare or public health sectors. The rest are generally called upon only during crises. “We need to formally recognize and support our community-based organizations with both adequate funding and technical assistance,” said Rita Carreón, Equity Advisory Council Member and Vice President for Health at UnidosUS. “The pandemic laid bare just how much CBO staff were undercompensated and not prioritized to receive PPE, vaccines or Covid tests. We can and should do better.”

The Council created 20 evidence-based recommendations based on the basic understanding that vaccine equity starts at the community level, and that efforts to build vaccine confidence and demand need to be prioritized as much as efforts to create vaccine supply. To do this, federal, state and local governments need to invest in communities and CBOs for sustained engagement, ensure community leaders are included as leaders and designers in initiatives, support equity-centered data collection, and build communications teams that include community leaders who can consistently adapt messages to meet local cultures and needs. Federal officials also need to do a better job of acknowledging uncertainty, telling stories, and using visuals...

The 13 members of the Equity Advisory Council are listed here.

Featured Journal Content
Remember the pandemic? Barely. Economist Impact, a policy research team within The Economist Group, supported by The Lancet’s publisher Elsevier, last week launched Confidence in Research—a report exploring attitudes of scientists to the practice and communication of science during the pandemic.

Based on a survey of over 3000 researchers worldwide, Economist Impact identified important actions that should be considered if mistakes are not to be repeated during future health emergencies. What were the key findings?

Inequalities in access to resources and funding for scientists worsened, especially for early career researchers, women, and those working in lower-income settings. Misinformation was a growing concern. Scientists took on more public-facing activities, disseminating and interpreting new research findings and countering false or misleading information. Although scientists recognised that there was a welcome increase in public attention to science, that awareness was not always matched by enhanced understanding. Researchers paid more attention to communicating uncertainties and limitations in their work. Their entry into the public sphere raised concerns about the oversimplification and politicisation of research. One challenge has been the avalanche of online abuse directed at scientists. Researchers sought more support to improve their communication skills when engaging with the public and policy makers.

Economist Impact made several proposals. Campaigns to counter misinformation. Investments to build public trust in science. Commissioning more research on science communication. Enhanced research literacy among the media. More vigorous efforts to explain new research findings to a public audience. Promoting more cross-country partnerships and making room for non-English speakers to reduce inequities. And preparing scientists for more public-facing roles—reducing administrative burdens, providing mentorship for early career researchers, training in communication, hiring science communicators, and providing support to confront online abuse.

I would add five additional challenges.
First, addressing the problem of speed. The demand for instant publication of new research was intense during the COVID-19 pandemic. So intense that peer review was routinely bypassed with an explosion of preprints. While understandable and probably necessary, I have misgivings. At The Lancet we see on a daily basis the value peer review brings to improving the science we publish. Omitting peer review has a cost.

Second, solving the problem of volume. The tidal wave of research papers that COVID-19 triggered may have reflected the remarkable agility of science to pivot during a crisis, but the pandemic also revealed that science today has a curation challenge. We have not developed effective means to select, organise, and present new research in a way that optimises understanding and application.
Third, managing the problem of voice. Those scientists with ready access to channels of communication were quickly and forcefully heard in the cacophony of an evolving global health crisis. But it was not the voices of the most powerful that the world always needed to hear. As new variants of SARS-CoV-2 emerged in Brazil, South Africa, and India, for example, scientists and clinicians from those countries deserved greater attention—attention they rarely received.

Fourth, the question of meaning. Just because research was published quickly did not mean that science policy makers read and responded to that research appropriately or in a timely manner. There were many examples during the pandemic of failures in science policy making, despite the availability of high-quality research. If science does not have effective institutional means for interpreting new findings, mistakes will be made.

And finally, dealing with error. Under severe pressure, miscalculations will be inevitable. The public and politicians should not think the worst of science or scientists if inadvertent errors are made. What matters is that those errors are identified and corrected as quickly as possible.

I hope the Confidence in Research initiative provokes actions across a diverse array of scientific institutions. But I am pessimistic. There is presently extraordinary complacency among many scientific bodies about the lessons of COVID-19. The attitude seems to be, “well, we developed effective vaccines in record time, didn’t we, so what is there to complain about?” It is an attitude that means we remain poorly prepared for coming health emergencies.

Confidence in research: researchers in the spotlight
An Economist Impact research programme supported by Elsevier
November 2022 :: 95 pages

Executive summary
Science and its practice are undergoing rapid change. The urgency of the pandemic accelerated open science and data sharing across borders, broadening access to research. Virtual collaborations amongst academic researchers and corporate R&D, as well as interdisciplinary and international collaboration helped to drive the extraordinary pace of innovation and breakthroughs. The pandemic also cemented the role of social media as a place for researchers to share their research, engage with others and debate findings. Much of this has been positive for science and academic research more broadly. But the experience of the last two years has also highlighted serious challenges facing the research community.

The huge quantities of information, increasingly publicised before peer review, poses challenges to identifying information that can be relied upon, even for seasoned researchers. This information must be synthesised and shared with the public, media, and policymakers, and researchers are increasingly the messengers. But what are the longer-term impacts of this? Are researchers prepared for this public-facing role? Are they equipped to communicate complex, often nuanced findings to lay audiences? And are they confident that the research community is providing them with support and incentive structures that are fit-for-purpose amidst this new landscape?
Our collective ability to tackle the most pressing global challenges, from climate change to future pandemics, depends on research, and on public trust in research. These challenges are monumental on their own, but amid the backdrop of increasing misinformation and politicisation of science, it is critical to understand whether researchers themselves have confidence in the research landscape, and in their abilities to take on this more public-facing role.

Confidence, as we define it, is two-fold: on the one hand, it relates to researchers’ self-confidence, and whether they have confidence in the integrity of research, in research processes and outcomes, in their research skills, and in their careers as researchers. On the other, it accounts for the confidence that researchers have in their relationships with the wider research community, from funders and policymakers to the media, the public, corporations, publishers, and their universities...

Key findings:
The impacts of the pandemic: tackling inequality and misinformation
:: Early career researcher, those in the Global South and, to a lesser extent, women respondents were more likely to feel the pandemic exacerbated inequalities in access to funding and resources.
:: Misinformation was cited as a growing concern, with over two thirds of survey respondents saying that the pandemic increased the importance of separating good quality research from misinformation.
:: Amidst these concerns, respondents still rely on peer review and methodological robustness when deciding whether to cite another piece of research.
:: The pandemic may also be affecting how some researchers in our survey perceive their primary role in society.

Conducting research in public view: a more public-facing researcher
:: Two thirds of researchers surveyed feel the pandemic has increased public attention on research, but less than 40% believe that better public understanding of how research is conducted will be a legacy of the pandemic.
:: Public attention and concerns about misinformation may be leading surveyed researchers to adopt more careful research practices and rethink what topics they focus on.
:: A more public-facing role for researchers comes with trade-offs: opportunities for public involvement, policy influence and improving social outcomes are coming up against oversimplification and politicisation of research.

Confidence boost: supporting researchers to take on a more public role
:: Survey respondents think that personal connections are a greater determinant of whether research is used by policymakers than the substance of the research itself.
:: A third of respondents to our survey reported that they or a close colleague have experienced abusive or acrimonious communications when engaging online or on social media.
:: Opportunities for policymaker engagement, communication support and incentive reforms appear important for reaping the benefits of increased public attention without undermining confidence in research.

::::::
::::::
::::::
Weekly epidemiological update on COVID-19 - 16 November 2022

Overview
Globally, the number of new weekly cases increased by 2% during the week of 7 to 13 November 2022, as compared to the previous week, with over 2.3 million new cases reported. The number of new weekly deaths decreased by 30%, as compared to the previous week, with about 7400 fatalities reported. As of 13 November 2022, 632 million confirmed cases and 6.5 million deaths have been reported globally.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 13 November 2022**

Weekly Epidemiological and Operational updates
Last update: 11 Nov 2022
Confirmed cases :: 633 601 048
Confirmed deaths :: 6 596 542
Vaccine doses administered: 12 943 741 540

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 19 Nov 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]
Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 19 Nov 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

COVID-19 Global Targets and Progress Tracker - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

COVID Vaccines – OCHA:: HDX
**COVID-19 Data Explorer: Global Humanitarian Operations**

**COVID-19 Vaccine Roll-out**

**NOV 05 2022 | COVAX (WHO, GAVI, CEPI), UNDESA, Press Reports | DATA**

Global COVID-19 Figures: 121M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 13.0B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 380M

Other Delivered (Number of Doses): 400M

Total Delivered (Number of Doses): 790M

Total Administered (Number of Doses): 530M

--------

**Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.


---

**Duke – Launch and Scale Speedometer**

**The Race for Global COVID-19 Vaccine Equity**

See our COVID Vaccine Purchases research

See our COVID Vaccine Manufacturing research

See our COVID Vaccine Donations & Exports research
:: 68.4% of the world population has received at least one dose of a COVID-19 vaccine.
:: 12.96 billion doses have been administered globally, and 2.11 million are now administered each day.
:: 24.4% of people in low-income countries have received at least one dose.

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/
**U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment**

**HHS**

*News*

No new digest content identified.

**FDA**

*Press Announcements*

No new digest content identified.

---

**Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**European Medicines Agency**

*News & Press Releases*

1. **News: European Antibiotic Awareness Day 2022: Preventing antimicrobial resistance together (new)**
   
   Last updated: 18/11/2022

2. **News: Sales of antibiotics for animal use have almost halved between 2011-2021 (new)**
   
   Last updated: 18/11/2022
Ebola outbreak in Uganda, as of 17 November 2022
Epidemiological update - 18 Nov 2022

Weekly COVID-19 country overview
Epidemiological update - 18 Nov 2022

35 000 annual deaths from antimicrobial resistance in the EU/EEA
Press release - 17 Nov 2022

Joint ECDC-WHO/Europe monkeypox surveillance bulletin
Epidemiological update - 9 Nov 2022

Monkeypox situation update, as of 8 November 2022
Epidemiological update - 9 Nov 2022

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations.]

China reports 24,473 new COVID cases; some Beijing businesses shut
Reuters
November 19, 20225:33 AM EST  Last Updated 17 hours ago

SHANGHAI, Nov 19 (Reuters) - China reported a slight decline in new COVID-19 cases on Saturday as numerous cities battled outbreaks, and as restaurants and other businesses in Beijing shut after authorities urged people to stay home over the weekend.
Authorities have recently sought to ease the impact of their tough zero-COVID policy, which is battering the world's second-biggest economy and sowing frustration and anger as case numbers have risen to their highest since April...

Asia
As China eases coronavirus restrictions, confusion and angst follow
By Christian Shepherd and Lyric Li
Washington Post, November 19, 2022 at 1:00 a.m. EST

PHEIC
Monkeypox
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-outbreak-2022

Multi-country outbreak of monkeypox, External situation report #10 - 16 November 2022

PHEIC
Polio

Polio this week as of 09 November 2022 - GPEI
:: GPEI midterm evaluation of Gender Equality Strategy published. Click here for more.

Summary of new polioviruses this week:
- Afghanistan: two WPV1 positive environmental samples
- DR Congo: six cVDPV1 cases and 17 cVDPV2 cases
- Nigeria: three cVDPV2 positive environmental samples
- Yemen: four cVDPV2 cases

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
No new digest content identified.

Northern Ethiopia
Ethiopia - Situation Report, 17 Nov 2022

Somalia
Ukraine
Highlights Last Updated: 16 Nov 2022
- Continuing attacks on energy infrastructure are leading to a major energy crisis in the country, with repeated cuts and power outages, including in the capital Kyiv.
- Over 165,000 people in villages retaken by Ukraine, including the city of Kherson, face dire humanitarian situation due to extensive damages and destruction of infrastructure.
- The priority of the humanitarians remains timely and critical assistance to recently retaken areas of Ukraine and addressing challenges related to winter and power cuts.
- During last four weeks, humanitarians sent at least seven convoys to support the people in retaken areas of Kharkivska and Khersonska oblast, including the city of Kherson.

WHO & Regional Offices [to 19 Nov 2022]
https://www.who.int/news
Selected News/Announcements/Statements
18 November 2022
News release
Quadripartite launches a new platform to tackle antimicrobial resistance threat to human and animal health and ecosystems

18 November 2022
Departmental news
Tackling emerging antimalarial drug resistance in Africa

17 November 2022
Departmental news
Progress and pathway towards elimination of cervical cancer among women living with HIV

16 November 2022
Departmental news
WHO and FP2030 to strengthen cooperation for sexual and reproductive health and rights

16 November 2022
Departmental news
Updated interim guidance for monkeypox vaccination published

14 November 2022
Departmental news
Joining forces to enable access to essential prevention and care services for people with diabetes and TB

:::::::
WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region
:: WHO steps up support to Uganda’s evolving Ebola outbreak as hope for vaccines increases
17 November 2022

WHO Region of the Americas PAHO
:: PAHO develops roadmap to curb spread of meningitis in the Americas by 2030
Lima, Peru, November 17, 2022 (PAHO) – Health experts and partners from the Americas involved in meningitis prevention, control and treatment gathered at a Pan American Health Organization (PAHO) conference this week to develop a roadmap to defeat meningitis in the Region by 2030. Although bacterial meningitis is preventable with...
:: PAHO/WHO supports Belize in the aftermath of hurricane Lisa
Washington, D.C., November 18, 2022 (PAHO) – The Pan American Health Organization/World Health Organization (PAHO/WHO) is supporting Belize to address medical needs and ensure the continuation of health services in areas devastated by the recent passage of hurricane Lisa. Lisa made landfall in Belize on 2 November as a Category One hurricane...
:: “The benefits are enormous and can be practiced even if the baby is in the NICU,” said a Trinidad and Tobago specialist about skin-to-skin contact in premature babies
Montevideo. November 17, 2022. There were tense moments in the Neonatal Intensive Care Unit at the Port of Spain General Hospital in Trinidad and Tobago. "There was a very sick premature baby. It was a ventilated baby, less than 800 grams," says neonatologist Marlon Timothy, chairman of the National Neonatology Committee of Trinidad and Tobago...
:: Countries must be vigilant of “triple threat” of COVID-19, influenza and RSV as holidays approach, PAHO Director says
Washington D.C. 16 November 2022 (PAHO) – With an increase in COVID-19 infections in the region, seasonal influenza on the rise, and a spike in cases of Respiratory Syncytial Virus (RSV), the Pan American Health Organization (PAHO) Director, Carissa F. Etienne, called on countries to implement the tools proven to keep communities safe, including...

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: 18 November 2022  News release
WHO/ECDC report: antimicrobial resistance a serious threat to patient safety in European Region

WHO Western Pacific Region
No new digest content identified.

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.
16 November 2022 | Middle East respiratory syndrome coronavirus (MERS-CoV) - Saudi Arabia

::::::

New WHO Publications
https://www.who.int/publications/i

Selected Titles
18 November 2022
Strategy to respond to antimalarial drug resistance in Africa

18 November 2022
Elimination of human onchocerciasis: progress report, 2021

17 November 2022
Preparing for certification of malaria elimination, second edition

17 November 2022
Thirteenth Meeting of the WHO South-East Asia Regional Immunization Technical Advisory Group

16 November 2022
Background document for the SAGE October 2022 session on monkeypox vaccines

16 November 2022
Annexes to the Vaccines and immunization for monkeypox interim guidance

16 November 2022
Vaccines and immunization for monkeypox: Interim guidance, 16 November 2022

16 November 2022
Middle East respiratory syndrome: global summary and assessment of risk - 16 November 2022

15 November 2022
Kenya national action plan on antimicrobial resistance: review of progress in the human health sector

::::::

CDC/ACIP [U.S.] [to 19 Nov 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases
No new digest content identified.
ACIP Meetings

Next ACIP Meeting
No 2022 meetings identified.

---

MMWR Weekly: Current Volume (71)
November 18, 2022 / No. 46
PDF of this issue

- Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
- Perception of Local COVID-19 Transmission and Use of Preventive Behaviors Among Adults with Recent SARS-CoV-2 Infection — Illinois and Michigan, June 1–July 31, 2022
- Sociodemographic Variation in Early Uptake of COVID-19 Vaccine and Parental Intent and Attitudes Toward Vaccination of Children Aged 6 Months–4 Years — United States, July 1–29, 2022

---

Coronavirus Disease 2019 (COVID-19) - CDC
Announcements/reports/data summaries.

---

Africa CDC  [to 19 Nov 2022]
http://www.africacdc.org/

News
Africa CDC, in collaboration with ASLM, FIND, and CHAI, launched a Consultative Workshop on Revised COVID-19 Testing and Surveillance Strategy
16 November 2022

---

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China  [to 19 Nov 2022]
http://en.nhc.gov.cn/

News
Nov 19: Daily briefing on novel coronavirus cases in China
On Nov 18, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 2,137 new cases of confirmed infections.

---

National Medical Products Administration – PRC  [to 19 Nov 2022]
http://english.nmpa.gov.cn/

Chinese mainland reports 2,276 new local confirmed COVID-19 cases
2022-11-18
  The Chinese mainland on Thursday reported 2,276 locally transmitted confirmed COVID-19 cases, the National Health Commission said Friday.

CCDC Weekly Reports: Current Volume (4)
2022-11-18 / No. 46
PDF of this issue
- Methods and Applications: Isolation and Characterization of Monkeypox Virus from the First Case of Monkeypox — Chongqing Municipality, China, 2022
- Methods and Applications: Epidemic Surveillance of Influenza Infections: A Network-Free Strategy — Hong Kong Special Administrative Region, China, 2008–2011
- Methods and Applications: Uncovering the Impact of Control Strategies on the Transmission Pattern of SARS-CoV-2 — Ruili City, Yunnan Province, China, February–March 2022
- Outbreak Reports: An Outbreak of SARS-CoV-2 Omicron Subvariant BA.2.76 in an Outdoor Park — Chongqing Municipality, China, August 2022

Organization Announcements

Paul G. Allen Frontiers Group  [to 19 Nov 2022]
https://alleninstitute.org/news-press/
News
Lake Conferences
November 9, 2022
  Circuit Neuroscience Basel and the Allen Institute are pleased to announce the Lake Conferences aiming to provide stimulating forums to broad research communities in key developing areas of neuroscience.

BMGF - Gates Foundation  [to 19 Nov 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
Nov 17, 2022
Bill & Melinda Gates Foundation Reaffirms Commitment to African Countries to Help Accelerate Progress in Health, Agriculture, Gender Equality, and Other Critical Areas

Bill & Melinda Gates Medical Research Institute  [to 19 Nov 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of
mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people

News: Articles and Publications
No new digest content identified.

**CARB-X** [to 19 Nov 2022]
https://carb-x.org/
News
No new digest content identified.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 19 Nov 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of *Vaccines and Global Health: The Week in Review* are available here.

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 19 Nov 2022]
http://cepi.net/
Latest News
No new digest content identified.

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 19 Nov 2022]
https://cioms.ch/
News; Publications
*CIOMS Special Newsletter: Fighting antimicrobial resistance*
14 Nov 2022
The fifth CIOMS Special Newsletter is dedicated to supporting the World Antimicrobial Awareness Week 2022. It describes the fight against the ongoing silent pandemic of antimicrobial resistance, and gives references for further reading. The Newsletter is available here.

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 19 Nov 2022]
https://www.darpa.mil/news
News
No new digest content identified.

**Duke Global Health Innovation Center** [to 19 Nov 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.
EDCTP  [to 19 Nov 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center  [to 19 Nov 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative  [to 19 Nov 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified

Evidence Aid  [to 19 Nov 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Hospital management preparedness tools for biological events
Added November 14, 2022

Fondation Merieux  [to 19 Nov 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi  [to 19 Nov 2022]
https://www.gavi.org/
News Releases
No new digest content identified.

GHIT Fund  [to 19 Nov 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified.

Global Fund  [to 19 Nov 2022]
Global Fund Board Hails Record-Breaking Seventh Replenishment Final Outcome of US$15.7 Billion

The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria welcomed the Seventh Replenishment outcome of US$15.7 billion during a 3-day meeting this week in Geneva. This comes two months after a successful pledging conference in New York th...

Global Fund Praises Italy’s Increased Pledge to Seventh Replenishment

The Global Fund to Fight AIDS, Tuberculosis and Malaria applauds today’s announcement by Italy of a €185 million pledge for the upcoming three-year period to help the world get back on track to end HIV, TB and malaria as public health threats by 2030...

Global Fund Applauds UK Pledge to Seventh Replenishment

The Global Fund warmly welcomes the decision by the United Kingdom to renew its strong commitment to help end AIDS, tuberculosis and malaria and strengthen health and community systems around the world. Minister for Development Andrew Mitchell announ...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 19 Nov 2022]
https://www.glopid-r.org/news/
News
Upcoming COVID CIRCLE conference ‘Beyond the pandemic: the impact of the COVID-19 research response in low- and middle-income countries’
November 18, 2022

Hilleman Laboratories [to 19 Nov 2022]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 19 Nov 2022]
https://www.hhmi.org/news
Press Room
Nov 15 2022
Institute
HHMI Statement in Support of eLife and Open Science Innovation
The journal eLife recently announced a new scientific publishing model. Starting in January 2023, eLife will no longer make accept/reject decisions after peer review. Instead, every preprint that eLife sends for peer review will be published on eLife’s website as a “Reviewed Preprint” together with an eLife assessment, public reviews, and a response from the authors. This means that eLife authors – not
editors – will decide whether and with what revisions an eLife article will be published. HHMI enthusiastically supports eLife’s new model.

**Human Vaccines Project** [to 19 Nov 2022]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

**IAVI** [to 19 Nov 2022]
https://www.iavi.org/
Latest News
FEATURES
November 17, 2022
*Meet the IAVI scientist who leads the team that is the first from an LMIC to report potent monoclonal neutralizing antibodies against SARS-CoV-2*

**ICRC** [to 015 Oct 2022]
What’s New [Selected]
No new digest content identified.

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
Selected Statements, Press Releases, Research
No new digest content identified.

**IFFIm**
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

**IFRC** [to 19 Nov 2022]
Press Releases [Selected]
*COP27: Negotiations are missing the ambition needed to protect those hardest hit by climate change, warns IFRC*
15/11/2022 | Press release

**Institut Pasteur** [to 19 Nov 2022]
Press Documents
No new digest content identified.

**ISC / International Science Council** [to 22 Oct 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Current Blogs
**There are 8 years left to meet the UN Sustainable Development Goals, but is it enough time?**
18.11.2022

**International Union of Immunological Societies (IUIS)**
https://iuis.org/
News/Events [Selected]
No new digest content identified.

**IVAC** [to 19 Nov 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

**IVI** [to 19 Nov 2022]
http://www.ivi.int/
IVI News & Announcements
**SK bioscience makes donation to IVI to support global R&D**
:: SK bioscience, IVI convene consultative meeting to discuss cooperation for next pandemic
:: Company announces KRW3 billion donation to IVI to support advancement of global vaccine R&D
November 17, 2022, SEOUL, Republic of Korea

**Johns Hopkins Center for Health Security** [to 19 Nov 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News [Selected]
No new digest content identified.

**MSF/Médecins Sans Frontières** [to 19 Nov 2022]
http://www.msf.org/
Latest [Selected Announcements]
Lebanon
**Access to vaccines and clean water essential as cholera spreads in Lebanon**
Press Release 18 Nov 2022
**Haiti**

**Vaccines and urgent response needed as cholera wave rises**
Press Release 17 Nov 2022

**Refugees, IDPs and people on the move**

**Serious medical issues caused by unlawful detention of migrants in Latvia**
Press Release 15 Nov 2022

---

**National Academy of Medicine** - USA  [to 19 Nov 2022]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

**National Academy of Sciences** - USA  [to 19 Nov 2022]
News
No new digest content identified.

**National Vaccine Program Office** - U.S. HHS  [to 19 Nov 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

**NIH**  [to 19 Nov 2022]
http://www.nih.gov/
News Releases
No new digest content identified.

**PATH**  [to 19 Nov 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

**Rockefeller Foundation**  [to 19 Nov 2022]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
Nov 15 2022
Press Releases
**Public Health and Equity Leaders Release Recommendations for Expanding Covid-19 Vaccine Equity**
The Rockefeller Foundation Equity Advisory Council outlines 20 actions to support vaccine and health equity in transition from response to recovery NEW YORK | November 14, 2022

**Sabin Vaccine Institute** [to 19 Nov 2022]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

**UNAIDS** [to 19 Nov 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
17 November 2022
**United for ending cervical cancer, HIV and inequities for women and girls**

16 November 2022
**Delays in global, affordable access to long-acting, injectable HIV medicines would cost lives, say AIDS campaigners**

**UNICEF** [to 22 Oct 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
No new digest content identified.

**Unitaid** [to 19 Nov 2022]
https://unitaid.org/
Featured News
17 November 2022
**Unitaid and global health partners reach 90% treatment target for women screened with cervical cancer in multi-country pilots**

14 November 2022
**World Pneumonia Day: Unitaid’s work to enhance global access to medical oxygen will contribute to reducing childhood mortality**

**Vaccine Equity Cooperative [nee Initiative]** [to 19 Nov 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 19 Nov 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

**Vaccine Confidence Project** [to 19 Nov 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 19 Nov 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
**Vaccine Update for Providers**
November 2022
Announcements: Vaccine Update schedule, December webinar reminder, Spanish VEC videos, and resources related to flu vaccine ingredients

**Wellcome Trust** [to 19 Nov 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

**The Wistar Institute** [to 22 Oct 2022]
Media
No new digest content identified.

**WFPHA: World Federation of Public Health Associations** [to 19 Nov 2022]
https://www.wfpha.org/
Latest News - Blog
**Protecting Health Workforce through Vaccination in Low-income & Low-Middle-income Countries**
Nov 17, 2022

**World Bank** [to 015 Oct 2022]
All News
**Central Asian Countries Show Commitment to a Cross-regional Approach to Pandemic Prevention**
ALMATY, November 14, 2022 – Government officials representing health, environment, and agriculture sectors from all of Central Asian countries participated in a regional ministerial meeting Protecting...
Date: November 14, 2022 Type: Press Release Language: English
** Remarks by World Bank Group President David Malpass at the G20 Launch Event for the Pandemic Fund in Bali, Indonesia**

Thank you, President Widodo and Minister Sri Mulyani for your leadership and Dr. Tedros for your coordination on this initiative. I’m now on my way to Bali and I look forward to seeing you soon. It’s great...

Date: November 13, 2022 Type: Statement

---

**World Customs Organization – WCO** [to 015 Oct 2022]

http://www.wcoomd.org/

**Latest News**

16 November 2022

**WCO hosts the 9th Rights Holders Consultative Group Meeting**

---

**World Medical Association [WMA]** [to 19 Nov 2022]


Press Releases

No new digest content identified.

---

**World Organisation for Animal Health (OIE)** [to 19 Nov 2022]

https://www.oie.int/en/

Press Releases, Statements

**Antimicrobial resistance: Now is the time for collective action**

Published on 18 November 2022

Quadripartite launches new Antimicrobial Resistance Multi-Stakeholder Partnership Platform to help tackle common threat to human and animal health and ecosystems

---

**WTO - World Trade Organisation** [to 19 Nov 2022]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events [Selected]

No new digest content identified.

---

**ARM [Alliance for Regenerative Medicine]** [to 19 Nov 2022]


Selected Press Releases

No new digest content identified.

---

**BIO** [to 19 Nov 2022]


Press Releases

No new digest content identified.
DCVMN – Developing Country Vaccine Manufacturers Network  [to 19 Nov 2022]
http://www.dcvmn.org/
News; Upcoming events
DCVMN Rebranding
November 14, 2022

ICBA – International Council of Biotechnology Associations  [to 19 Nov 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA  [to 19 Nov 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

International Alliance of Patients’ Organizations – IAPO  [to 19 Nov 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
Press Releases
IGBA Reiterates its Yearly Call to Join the Biosimilars Movement on Advancing Access (November 2022)
Geneva, November 14, 2022 – In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients.

PhRMA  [to 19 Nov 2022]
http://www.phrma.org/
Press Releases
No new digest content identified.

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases
AstraZeneca ranked in top three in the Access to Medicine Index
15 November 2022

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - Website not responding at inquiry

Biological E
News - No new digest announcements identified

BioNTech
Press Releases
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
18 November 2022

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
16 November 2022

BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore
13 November 2022

Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinnagen
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.
GSK
*Press releases for media*
15 November 2022

**GSK tops Access to Medicine Index (ATMI) for eighth consecutive time**
Company also announces £100 million investment over next ten years to support access initiatives in lower income countries

14 November 2022

**GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis**
Results demonstrate the potential for this asset to be a component of simpler TB treatment regimens in the future.

**IMBCAMS, China**
*Home* - Website not responding at inquiry

**Janssen/JNJ**
*Press Releases* - No new digest announcements identified

**Medicago**
*Media* - No new digest announcements identified

**Merck**
*News releases* - No new digest announcements identified

**Moderna**
*Press Releases*
14 November, 2022

**Moderna’s BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial**

**Nanogen**
*News* - No new digest announcements identified

**Novartis**
*News* - No new digest announcements identified

**Novavax**
*Press Releases*
Nov 18, 2022

**Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults**

**Pfizer**
*Recent Press Releases*
11.18.2022
**Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages**

**R-Pharm**
[No news or media page identified]

**Sanofi Pasteur**
[Press Releases] -- No new digest announcements identified

**Serum Institute of India**
[NEWS & ANNOUNCEMENTS] - No new digest announcements identified

**Shifa Pharmed [Iran]**
No news page identified.

**Sinopharm/WIBPBIBP**
[News] - No new digest announcements identified

**Sinovac**
[Press Releases]
[SINOVAC's EV71 Enterovirus Type 71 (EV71) vaccine, Inlive®, Vaccine Inlive® Approved in Indonesia]
2022/11/18

**SK Biosciences**
[Press Releases]
[SK bioscience Donates to International Vaccine Institute to Support Global Vaccine R&D]
SK bioscience and IVI had a conference to discuss a cooperation against the next pandemic SK de...
2022.11.17

**Takeda**
[Newsroom] - No new digest announcements identified

**Valneva**
[Press Releases] - No new digest announcements identified

**Vector State Research Centre of Viralogy and Biotechnology**
[Home] - Website not responding [404 error]

**WestVac Biopharma**
[Media] - No new digest announcements identified

**Zhifei Longcom, China**
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]  
[No website identified]
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 4
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 11: E1029-1106 Nov 2022
https://journalofethics.ama-assn.org/issue/how-much-will-it-cost
How Much Will It Cost?

An honest answer to the question, How much will it cost? is what most people seeking price transparency in health care tend to be after. Yet, what health care costs you or your family, or even being given an opportunity to assess whether you can afford services, is not how price transparency in health care is defined by even the most dedicated, knowledgeable advocates. A 2014 report from a landmark task force of the Healthcare Financial Management Association, for example, states that what all patients deserve from health care price transparency is “accurate price estimates from a reliable source.” If this is the best definition of price transparency that a well-intentioned, well-informed task force suggests the American public can expect, one might reasonably suspect that, without dramatic reforms to financial structures of US health care, an honest answer to the question, How much will it cost? might not even be possible in many cases. This theme issue investigates why this problem matters clinically and ethically to every stakeholder, rich or poor, in the US health care system.
[Reviewed earlier]
American Journal of Infection Control
November 2022  Volume 50  Issue 1  1p1193-1280
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
November 2022  Volume 63  Issue 5  p669-874
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
November 2022  112(11)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Volume 107 (2022): Issue 4_Suppl (Oct 2022)
https://www.ajtmh.org/view/journals/tpmd/107/4_Suppl/tpmd.107.issue-4_Suppl.xml
International Centers of Excellence for Malaria Research (ICEMR): Achievements in the Last Decade
[Reviewed earlier]

Annals of Internal Medicine
November 2022  Volume 175, Issue 11
http://annals.org/aim/issue
Reviews
FREE
Georgia Salanti, PhD, et al

Position Papers
Environmental Health: A Position Paper From the American College of Physicians
FREE
Ryan Crowley, BSJ, Suja Mathew, MD, and David Hilden, MD, MPH, for the ... View all authors
Pages:1591–1593

Supporting the Health and Well-Being of Indigenous Communities: A Position Paper From the American College of Physicians
FREE
Josh Serchen, BA,... View all authors
Pages:1594–1597

Editorials
**Environmental Health: Translating Policy Into Action**
Emily Senay, MD, MPH and Andrew Hantel, MD
Pages:1612–1613

**Artificial Intelligence – An International Journal**
Volume 312  November 2022
[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**
http://resource-allocation.biomedcentral.com/
(Reviewed earlier)

**BMJ Global Health**
November 2022 - Volume 7 - 11
https://gh.bmj.com/content/7/11
[Reviewed earlier]

**BMC Health Services Research**
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 19 Nov 2022)

**Attitude towards COVID-19 vaccination among healthcare workers: a cross sectional study from Egypt**
Herd immunity is necessary to contain the coronavirus disease 2019 (COVID-19) pandemic. Vaccination is the fastest and safest pandemic control strategy. Healthcare workers (HCWs) are essential in providing vac...
Authors: Samar Tharwat, Dalia Kamal Nassar, Mohammed Kamal Nassar, Ahmed Mohammed Saad and Fatma Hamdy
Citation: BMC Health Services Research 2022 22:1357
Content type: Research Published on: 16 November 2022

**BMC Infectious Diseases**
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 19 Nov 2022)

**A booster hepatitis B vaccine for children with maternal HBsAg positivity before 2 years of age could effectively prevent vaccine breakthrough infections**
The long-term protective effect of hepatitis B vaccine (HepB), the incidence of hepatitis B virus (HBV) vaccine breakthrough infections (VBIs), and whether a booster HepB is necessary remain to be clarified in...
Authors: Yarong Song, Xin Zhang, Minmin Liu, Xiangjun Zhai, Jianxun Liu, Yi Li, Lili Li, Yiwei Xiao, Zhongping Duan, Jing Jiang, Feng Ding, Lingyu Zhu, Jie Jiang, Huaibin Zou, Hui Zhuang, Jie Wang...
Citation: BMC Infectious Diseases 2022 22:863
**Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy**

We aimed to assess harms (post-vaccine myocarditis and pericarditis) and benefits (preventing severe disease) of COVID-19 vaccination.

Authors: Giovanni Corrao, Matteo Franchi, Danilo Cereda, Francesco Bortolan, Olivia Leoni, Eugenio Vignati, Giovanni Pavesi and Andrea Gori

Citation: BMC Infectious Diseases 2022 22:844

**BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content

(Accessed 19 Nov 2022)

**Ethical preparedness in health research and care: the role of behavioural approaches**

Public health scholars have long called for preparedness to help better negotiate ethical issues that emerge during public health emergencies. In this paper we argue that the concept of ethical preparedness ha...

Authors: G. Samuel, L. M. Ballard, H. Carley and A. M. Lucassen

Citation: BMC Medical Ethics 2022 23:115

**What information and the extent of information to be provided in an informed assent/consent form of pediatric drug trials**

This study aimed to determine the elements and the extent of information that child participants and their parents would like to read in an informed assent form (IAF)/informed consent form (ICF) of a pediatric...

Authors: Nut Koonrungsesomboon, Pimlak Charoenkwan, Rungrote Natesiriinikul, Kanda Fanhchaksai, Wannachai Sakuludomkan and Nimit Morakote

Citation: BMC Medical Ethics 2022 23:113

**Needs to address clinicians’ moral distress in treating unvaccinated COVID-19 patients**

Moral dilemmas have arisen concerning whether physicians and other providers should treat patients who have declined COVID vaccination and are now sick with this disease. Several ethicists have argued that cli...

Authors: Robert Klitzman

Citation: BMC Medical Ethics 2022 23:110

**BMC Medicine**

http://www.biomedcentral.com/bmcmed/content

(Accessed 19 Nov 2022)

**Assessing the feasibility of sustaining SARS-CoV-2 local containment in China in the era of highly transmissible variants**
The SARS-CoV-2 containment strategy has been successful in mainland China prior to the emergence of Omicron. However, in the era of highly transmissible variants, whether it is possible for China to sustain a ...

Authors: Yan Wang, Kaiyuan Sun, Zhaomin Feng, Lan Yi, Yanpeng Wu, Hengcong Liu, Quanyi Wang, Marco Ajelli, Cécile Viboud and Hongjie Yu
Citation: BMC Medicine 2022 20:442
Content type: Research article Published on: 15 November 2022

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 19 Nov 2022)
[No new digest content identified]

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 19 Nov 2022)
**Amplified effect of social vulnerability on health inequality regarding COVID-19 mortality in the USA: the mediating role of vaccination allocation**
Vaccination reduces the overall burden of COVID-19, while its allocation procedure may introduce additional health inequality, since populations characterized with certain social vulnerabilities have received ...  
Authors: Ying Chen, Lanwei Zhang, Tenglong Li and Li Li
Citation: BMC Public Health 2022 22:2131
Content type: Research Published on: 19 November 2022

**COVID-19 risk perception framework of the public: an infodemic tool for future pandemics and epidemics**
Understanding the risk perceptions of the public is central for risk communications and infodemic management during emergency and preparedness planning as people’s behavior depends on how they perceive the rel...
Authors: Anna-Leena Lohiniva, Annika Pensola, Suvi Hyökki, Jonas Sivelä and Tuukka Tammi
Citation: BMC Public Health 2022 22:2124
Content type: Research Published on: 18 November 2022

**Impact of HPV vaccination on HPV infection and cervical related disease burden in real-world settings (HPV-RWS): protocol of a prospective cohort**
Cervical cancer is one of the most common cancers in women and could be prevented by human papilloma virus (HPV) vaccination. Cervarix, the first available HPV vaccine, has been widely administrated to Chinese wo...
Authors: Zhike Liu, Pei Li, Xueyang Zeng, Xiaoying Yao, Yexiang Sun, Hongbo Lin, Peng Shen, Feng Sun and Siyan Zhan
Citation: BMC Public Health 2022 22:2117
Content type: Study protocol Published on: 18 November 2022

**Measles second dose vaccine utilization and associated factors among children aged 24–35 months in Sub-Saharan Africa, a multi-level analysis from recent DHS surveys**
Although a safe and effective vaccine is available, measles remains an important cause of mortality and morbidity among young children in Sub-Saharan Africa (SSA). The WHO and UNICEF recommended measles-contai...

Authors: Dagmawi Chilot, Daniel Gashaneh Belay, Kegnie Shitu, Yibeltal Yismaw Gela, Mihret Getnet, Bezawit Mulat, Atalay Goshu Muluneh, Mehari Woldemariam Merid, Desalegn Anmut Bitew and Adugnaw Zeleke Alem

Citation: BMC Public Health 2022 22:2070
Content type: Research Published on: 12 November 2022

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 19 Nov 2022)
[No new digest content identified]

BMJ Evidence-Based Medicine
October 2022 - Volume 27 - 5
https://ebm.bmj.com/content/27/5
[Reviewed earlier]

BMJ Open
September 2022 - Volume 12 - 9
https://bmjopen.bmj.com/content/12/9
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 100(11); 2022 Nov 1
https://www.ncbi.nlm.nih.gov/pmc/issues/419724/
[Reviewed earlier]

Cell
Nov 10, 2022 Volume 185 Issue 23 p4249-4464
https://www.cell.com/cell/current
[Reviewed earlier]

Child Care, Health and Development
Volume 48, Issue 6 Pages: 881-1137 November 2022
https://onlinelibrary.wiley.com/toc/13652214/current
Special Issue: The Pervasive Effects of COVID-19 on Children: A Global Perspective
Issue Edited by: Jan Willian Gorter, Evelyn Culnane, Lyndal Hickey, Mark Ferro, Tony Okely
[Reviewed earlier]
Clinical Pharmacology & Therapeutics
Volume 112, Issue 5  Pages: 917-1130  November 2022
https://ascp.onlinelibrary.wiley.com/toc/15326535/current
[New issue; No digest content identified]

Clinical Therapeutics
September 2022  Volume 44  Issue 9  p1173-1268
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 19 Issue 6, December 2022
https://journals.sagepub.com/toc/ctja/19/6
Open Access  Research article  First published 22 July, 2022pp. 647–654
A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats
Ira M Longin

Ethics
Restricted access  Research article  First published 7 September, 2022pp. 681–689
Ethics challenges in sharing data from pragmatic clinical trials
Stephanie R Morain, Juli Bollinger, Kevin Weinfurt, Jeremy Sugarman

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 19 Nov 2022]
A literature review exploring how health systems respond to acute shocks in fragile and conflict-affected countries
Understanding how health systems respond to shocks has become a pressing need to strengthen response efforts. With already fragmented and disrupted health services, fragile and conflict affected [FCA] countries...
Authors: Kyaw Myat Thu, Sarah Bernays and Seye Abimbola
Citation: Conflict and Health 2022 16:60
Content type: Review Published on: 15 November 2022

Contemporary Clinical Trials
Volume 122  November 2022
[Reviewed earlier]

The CRISPR Journal
Volume 5, Issue 5 / October 2022
https://www.liebertpub.com/toc/crispr/5/5
Current Genetic Medicine Reports
Volume 10, issue 1, March 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-1

Current Opinion in Infectious Diseases
December 2022 - Volume 35 - Issue 6
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current

Developing World Bioethics
Volume 22, Issue 3 Pages: 123-180 September 2022
https://onlinelibrary.wiley.com/toc/14718847/current

Development in Practice
Volume 32, Issue 8, 2022
http://www.tandfonline.com/toc/cdip20/current

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 5 - October 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

Disasters
Volume 46, Issue 4 Pages: 853-1126 October 2022
https://onlinelibrary.wiley.com/toc/14677717/current

EMBO Reports
Volume 23 Issue 11 7 November 2022
**Expert Review of Vaccines**
Vol 21 (11) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

**Foreign Affairs**
Volume 101, Number 5   September/October 2022
https://www.foreignaffairs.com/issues/2022/101/5
[Reviewed earlier]

**Forum for Development Studies**
Volume 49, 2022 - Issue 3
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

**Genetics in Medicines**
Volume 24, Issue 11 Pages A1-A8, 2211-2418 (November 2022)
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/24/issue/11
[Reviewed earlier]

**Genome Medicine**
https://genomemedicine.biomedcentral.com/articles
[Accessed 19 Nov 2022]
[No new digest content identified]

**Global Health Action**
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**
Vol. 10, No. 5   October 31, 2022
http://www.ghspjournal.org/content/current
[Reviewed earlier]

**Global Legal Monitor – Library of Congress/USA**
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 19 Nov 2022]
[No new digest content identified]
(Re)imagining Research, Activism, and Rights at the Intersections of Sexuality, Health, and Social Justice
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 19 Nov 2022]
[No new digest content identified]

Health and Human Rights
Volume 24, Issue 1, June 2022
[Reviewed earlier]

Health Economics, Policy and Law
Volume 17 - Issue 4 - October 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 37, Issue 9, November 2022
https://academic.oup.com/heapol/issue/37/9
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 19 Nov 2022]
[No new digest content identified]

Human Gene Therapy
Volume 33, Issue 21-22 / November 2022
https://www.liebertpub.com/toc/hum/33/21-22
Open Access
Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
Jeffrey S. Moffit, et al.
Pages:1126–1141
Published Online:14 September 2022
The nonclinical safety assessments for gene therapies are evolving, leveraging over 20 years of experimental and clinical experience. Despite the growing experience with these therapeutics, there is no approved harmonized global regulatory documents for developing gene therapies with only the ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use) S12 guidance on nonclinical biodistribution currently under discussion. Several health authorities have issued guidance over the last 15 years on the nonclinical safety aspects for gene therapy products, but many of the recommendations are limited to high-level concepts on nonclinical safety aspects or altogether silent on key topics. Historically, this approach was appropriately vague given our relatively small dataset of nonclinical experience, where a comprehensive and detailed regulatory guidance approach was unlikely to be appropriate to address all scenarios. However, harmonization of key considerations and assumptions can provide a consistent basis for developing the appropriate nonclinical safety development plans for individual programs, reducing uncertainty across regulatory regions and unnecessary animal use. Several key areas of nonclinical safety testing are nearing maturation for a harmonized approach, including species selection, certain aspects of study design, study duration, and unintended genomic integration risks. Furthermore, several emerging topics are unaddressed in current regulatory guidance for gene therapy products, which will become key areas of differentiation for the next generation of therapeutics. These topics include redosing, juvenile/pediatric safety, and reproductive/developmental safety testing, where relevant experience from other modalities can be applied. The rationale and potential study design considerations for these topics will be proposed, acknowledging that certain aspects of gene therapy development are not considered appropriate for harmonization. This article provides an overview of the current nonclinical safety regulatory landscape, summarizes typical nonclinical safety study designs, highlights areas of uncertainty, and discusses emerging topics that warrant consideration. Specific recommendations and perspectives are provided to inform future regulatory discussions and harmonization efforts.

Free

Scientists' Views on Scientific Self-Governance for Human Genome Editing Research
R. Jean Cadigan, et al.
Pages:1157–1163
Published Online:22 August 2022
https://doi.org/10.1089/hum.2022.087

As research on human gene editing has grown, a variety of prominent international organizations are considering how best to govern such research. But what role do scientists engaged in genome editing think they should have in developing research governance? In this study, we present results from a survey of 212 U.S.-based scientists regarding views on human genome editing governance. Most did not believe that scientists should be allowed to self-govern human genome editing research. Open-ended responses revealed four main reasons: conflicts of interest, the inevitability of rare “bad apples,” historical evidence to the contrary, and the limitations of scientific expertise. Analyses of open-ended responses also revealed scientists' views on how human gene editing research should be governed. These views emphasize interdisciplinary professional and public input. The study results illustrate a noteworthy shift in the scientific community's traditional vision of professional autonomy and can inform ongoing efforts to develop research governance approaches.
Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

Immunity
Nov 08, 2022 Volume 5 Issue 11 p1967-2210
https://www.cell.com/immunity/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 19 Nov 2022]
HPV knowledge and vaccine acceptability: a survey-based study among parents of adolescents (KAPPAS study)
Human papillomavirus (HPV) infection is recognized as one of the major causes of infection-related cancer worldwide. In Spain, the HPV vaccination program started in 2007 and until 2022, it targeted 12-year-ol...
Authors: Noelia López, Ignacio Salamanca de la Cueva, Elena Taborga, Auxiliadora Fernández de Alba, Inés Cabeza, Reyes Mazas Raba, Josep Marès, Patricia Company, Bruno Herrera and Manuel Cotarelo
Citation: Infectious Agents and Cancer 2022 17:55
Content type: Research Article Published on: 17 November 2022

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 19 Nov 2022]
[No new digest content identified]

International Health
Volume 14, Issue 6, November 2022
https://academic.oup.com/inthealth/issue/14/6
[Reviewed earlier]

International Human Rights Law Review
Volume 11 (2022): Issue 1 (Jun 2022)
https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml
Table of Contents
[Reviewed earlier]
International Journal of Community Medicine and Public Health
Vol 9, No 11 (2022) November 2022
[New issue; No digest content identified]

International Journal of Epidemiology
Volume 51, Issue 5, October 2022
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 15 Issue 3, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3
Special Issue: Children, young people and their international human right to healthcare
[Reviewed earlier]

JAMA
November 15, 2022, Vol 328, No. 19, Pages 1889-1988
https://jamanetwork.com/journals/jama/currentissue
[New issue; No digest content identified]

JAMA Pediatrics
November 2022, Vol 176, No. 11, Pages 1061-1156
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
November 2022 - Volume 20 - Issue 11
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No relevant content identified]

Journal of Adolescent Health
November 2022 Volume 71 Issue 5 p521-654
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 75 (2022)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 6, December 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-6
[Reviewed earlier]

Journal of Development Economics
Volume 159  November 2022
[New issue; No relevant content identified]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 5, December 2022
http://journals.sagepub.com/toc/jre/current
Ethical Issues using Digital Surveillance Technologies in Research
Restricted access  Research article  First published 7 September, 2022pp. 573–586
Equitable Design and Use of Digital Surveillance Technologies During COVID-19: Norms and Concerns
Bridget Pratt, Michael Parker, Susan Bull

Journal of Epidemiology & Community Health
November 2022 - Volume 76 - 11
https://jech.bmj.com/content/76/11
[New issue; No relevant content identified]

Journal of Evidence-Based Medicine
Volume 15, Issue 3  Pages: 181-314  September 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 18, Issue 1, 2022
http://www.tandfonline.com/toc/rjge20/current
Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 4, November 2022
**Journal of Immigrant and Minority Health**
Volume 24, issue 5, October 2022

**Journal of Immigrant & Refugee Studies**
Volume 20, 2022 Issue 4
https://www.tandfonline.com/toc/wimm20/current

**Journal of Infectious Diseases**
Volume 226, Issue 7, 1 October 2022
https://academic.oup.com/jid/issue/226/7

**Journal of International Development**
Volume 34, Issue 8 Pages: 1453-1648 November 2022
https://onlinelibrary.wiley.com/toc/10991328/current

*RESEARCH ARTICLES*

**Global partnerships on paper and in practice: Critical observations from inside a Global Challenge Research Fund capacity-development project**
Richard Axelby, Bethel Worku-Dix, Emma Crewe
Pages: 1496-1508
First Published: 16 March 2022

**Journal of Medical Ethics**
November 2022 - Volume 48 - 11
http://jme.bmj.com/content/current
https://institutionalrepository.aah.org/jpcrr/

**Journal of Patient-Centered Research and Reviews**
Volume 9, Issue 3 (2022)
https://institutionalrepository.aah.org/jpcrr/

[Reviewed earlier]
Journal of Pediatrics
November 2022 Volume 250 p1-118
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[No new digest content identified]

Journal of Public Health Management & Practice
November/December 2022 - Volume 28 - Issue 6
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 43, issue 3, September 2022
https://link.springer.com/journal/41271/volumes-and-issues/43-3
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
November 2022 Volume 19 Issue 196
https://royalsocietypublishing.org/toc/rsif/current
[New issue; No digest content identified]

Journal of Travel Medicine
Volume 29, Issue 7, October 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 96 Number 18 September 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Offline: COVID-19—the lessons that science forgot
Richard Horton
Published: November 19, 2022 DOI: https://doi.org/10.1016/S0140-6736(22)02358-3
[See Milestones above for detail]

The Lancet Child & Adolescent Health
Nov 2022 Volume 6 Number 11 p747-828, e22-e23
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Nov 2022 Volume 4 Number 11 e765-e849
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Nov 2022 Volume 22 Number 11 p1513-1648, e310-e347
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Nov 2022 Volume 7 Number 11 e885-e982
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Nov 2022 Volume 10 Number 11 p1009-1098, e94-e106
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 26, issue 11, November 2022
Review Paper
Understanding Barriers and Facilitators to Maternal Immunization: A Systematic Narrative Synthesis of the Published Literature
Authors (first, second and last of 4)
Sarah Geoghegan, Sydney Shuster, Kristen A. Feemster
Published: 29 September 2022
Medical Decision Making (MDM)
Volume 42 Issue 8, November 2022
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 100, Issue 3  Pages: 617-961  September 2022
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Nature
Volume 611 Issue 7936, 17 November 2022
https://www.nature.com/nature/volumes/611/issues/7936
World View  15 Nov 2022
To beat Ebola in Uganda, fund what worked in Liberia
Enlist community members to find and support cases — trust is crucial to containment.
Mosoka P. Fallah

Nature Biotechnology
Volume 40 Issue 11, November 2022
https://www.nature.com/nbt/volumes/40/issues/11
[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 19 Nov 2022)
[No new digest content identified]

Nature Genetics
Volume 54 Issue 11, November 2022
https://www.nature.com/ng/volumes/54/issues/11
[Reviewed earlier]

Nature Human Behaviour
Volume 6 Issue 11, November 2022
https://www.nature.com/nathumbehav/volumes/6/issues/11
Editorial  16 Nov 2022
Climate change and human behaviour
Climate change is an immense challenge. Human behaviour is crucial in climate change mitigation, and in tackling the arising consequences. In this joint Focus issue between Nature Climate Change and Nature Human Behaviour, we take a closer look at the role of human behaviour in the climate crisis.

**Article** 25 Aug 2022

**Strategic COVID-19 vaccine distribution can simultaneously elevate social utility and equity**

The authors use data-informed computational modelling and show that prioritizing vaccination efforts for the most disadvantaged communities can simultaneously improve equity and prevent the spread of disease.

Lin Chen, Fengli Xu, Yong Li

**Article** 01 Sept 2022

**A citywide experiment testing the impact of geographically targeted, high-pay-off vaccine lotteries**

A citywide experiment tested the effects of three high-pay-off, geo-targeted lotteries to motivate adults to get a COVID-19 vaccine. Zip-code-targeted lotteries in which residents were given 50–100× boosts in their chances of a win did not result in higher vaccine uptake.

Katherine L. Milkman, Linnea Gandhi, Kevin G. Volpp

**Nature Medicine**

Volume 28 Issue 11, November 2022

https://www.nature.com/nm/volumes/28/issues/11

**Comment** 13 Oct 2022

**Data-enabled responses to pandemics: policy lessons from COVID-19**

Most health systems struggled to obtain and analyze real-time data during the COVID-19 pandemic, but places that succeeded can be studied to provide a model for data-enabled responses to future epidemics and pandemics.

Sangeeta Dhami, Deidre Thompson, Aziz Sheikh

**Comment** 26 Sept 2022

**The AI life cycle: a holistic approach to creating ethical AI for health decisions**

The ethical impact of AI algorithms in healthcare should be assessed at each phase, from data creation to model deployment, so that their use narrows rather than widens inequalities.

Madeleina Y. Ng, Supriya Kapur, Tina Hernandez-Boussard

**Review Article** 10 Nov 2022

**The landscape of mRNA nanomedicine**

The COVID-19 mRNA vaccines have transformed the field of mRNA nanomedicine, but this new class of therapeutics has the potential to treat many other diseases. This Review profiles the latest advances and challenges.

Xiangang Huang, Na Kong, Wei Tao

**Article Open Access** 06 Oct 2022

**Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial**
A bivalent vaccine encoding the ancestral and Beta variant SARS-CoV-2 spike proteins boosts neutralizing antibody responses against multiple viral variants, suggesting that a bivalent approach is an effective strategy to broadly enhance protection against COVID-19.
Spyros Chalkias, Frank Eder, Rituparna Das

Article Open Access 27 Oct 2022

Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic
Retrospective simulation of several global COVID-19 distribution scenarios shows that equitable and altruistic vaccine sharing strategies could have substantially reduced the global burden of SARS-CoV-2 infections and associated mortality.
Sam Moore, Edward M. Hill, Matt J. Keeling

Nature Reviews Drug Discovery
Volume 21 Issue 11, November 2022
https://www.nature.com/nrd/volumes/21/issues/11
[Reviewed earlier]

Nature Reviews Genetics
Volume 23 Issue 11, November 2022
https://www.nature.com/nrg/volumes/23/issues/11
[Reviewed earlier]

Nature Reviews Immunology
Volume 22 Issue 11, November 2022
https://www.nature.com/nri/volumes/22/issues/11
[Reviewed earlier]

New England Journal of Medicine
November 17, 2022 Vol. 387 No. 20
https://www.nejm.org/toc/nejm/medical-journal
Perspective
Monkeypox — A Sobering Sentinel for Pandemic Preparedness and Sexual Health System Capacity
M.R. Golden and J.N. Wasserheit

Original Articles
Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali
K. Kayentao and Others

Covid-19 Vaccine Protection among Children and Adolescents in Qatar
H. Chemaitelly and Others
**nPJP Vaccines**
https://www.nature.com/npjvaccines/
[Accessed 19 Nov 2022]
[No new digest content identified]

**Pediatrics**
Volume 150, Issue 5   November 2022
https://publications.aap.org/pediatrics/issue/150/5

*Articles*

**Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial**
Brandon J. Essink, MD; Marten Heeringa, PhD; Robert J. Jeanfreau, MD; Daniel Finn, MD; Vince Matassa, PhD ...

**Effectiveness of mRNA COVID-19 Vaccines in Adolescents Over 6 Months**
Emanuele Amodio, MD, PhD; Dario Genovese, MD; Luca Mazzeo, MD; Luca Martino, MD; Vincenzo Restivo, MD, PhD ...

**Pediatric Shared Decision-Making for Simple and Complex Decisions: Findings From a Delphi Panel**
Sarah M. Eaton, MD; Jonna D. Clark, MD, MA; Christy L. Cummings, MD; Alexander A. Kon, MD; Wynne Morrison, MD, MBE ...

**PharmacoEconomics**
Volume 40, issue 11, November 2022
[Reviewed earlier]

**PLoS Biology**
https://journals.plos.org/plosbiology/
(Accessed 19 Nov 2022)
[No new digest content identified]

**PLoS Genetics**
https://journals.plos.org/plosgenetics/
(Accessed 19 Nov 2022)
[No new digest content identified]

**PLoS Medicine**
http://www.plosmedicine.org/
(Accessed 19 Nov 2022)
[No new digest content identified]
PLoS Neglected Tropical Diseases
http://www.plosntds.org/
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 19 Nov 2022]
Research Article
Healthcare professionals’ perceptions and recommendations regarding adolescent vaccinations in Georgia and Tennessee during the COVID-19 pandemic: A qualitative research
Olufunto A. Olusanya, Brianna White, Fauzia Malik, Kyra A. Hester, Robert L. Davis, Robert A. Bednarczyk, Arash Shaban-Nejad
| published 18 Nov 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0277748

Assessment of COVID-19 vaccination among healthcare workers in Iraq; adverse effects and hesitancy
Omeed Darweesh, Nasir Khatab, Ramiar Kheder, Thulfiqar Mohammed, Tola Faraj, Sabah Ali, Muath Ameen, Azad Kamal-Aldin, Mohammed Alswes, Naif Al-Jomah
Research Article | published 18 Nov 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0274526

Addressing vaccine hesitancy in developing countries: Survey and experimental evidence
Christopher Hoy, Terence Wood, Ellen Moscoe
Research Article | published 17 Nov 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0277493

Factors related to COVID-19 vaccine intention in Latino communities
Adriana Perez, Julene K. Johnson, David X. Marquez, Sahru Keiser, Paula Martinez, Javier Guerrero, Thi Tran, Elena Portacolone
Research Article | published 15 Nov 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0272627

Influencing factor of COVID-19 vaccination trust and hesitancy in Wonju city, South Korea
Hocheol Lee, Eun Bi Noh, Ji Eon Kim, Juyeon Oh, Eun Woo Nam
Research Article | published 14 Nov 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0277016

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 19 Nov 2022]
[No new digest content identified]
Impact assessment of a provider-targeted national vaccine messaging campaign on human papillomavirus vaccination rates among US adolescent males
Denny Fe Agana-Norman, Abbey B. Berenson, Mihyun Chang
Article 107228

Tdap-HPV vaccination bundling in the USA: Trends, predictors, and implications for vaccine series completion
Yenan Zhu, Chi-Fang Wu, Anna R. Giuliano, Maria E. Fernandez, ... Kalyani Sonawane
Article 107218

Low human papillomavirus vaccine uptake among women engaged in HIV care in Ontario, Canada
Catharine Chambers, Jennifer Gillis, Joanne Lindsay, Anita C. Benoit, ... Ann N. Burchell
Article 107246

Multilevel determinants on COVID-19 booster intention among Americans
Feng Hao
Article 107269

Parental refusal and hesitancy of vaccinating children against COVID-19: Findings from a nationally representative sample of parents in the U.S.
Thadchaigeni Panchalingam, Yuyan Shi
Article 107288

Association between COVID-19 vaccine hesitancy and trust in the medical profession and public health officials
Diana Silver, Yeerae Kim, Elizabeth McNeill, Rachael Piltch-Loeb, ... David Abramson
Article 107311

**Proceedings of the Royal Society B**
09 November 2022  Volume 289  Issue 1986  
https://royalsocietypublishing.org/toc/rspb/current  
[Reviewed earlier]

**Public Health**
Volume 212  Pages 1-110 (November 2022)  
[Reviewed earlier]

**Public Health Ethics**
Volume 15, Issue 1, April 2022  
http://phe.oxfordjournals.org/content/current  
[Reviewed earlier]

**Public Health Reports**
Volume 137 Issue 6, November/December 2022  
https://journals.sagepub.com/toc/phrg/137/6  
*Case Report*  First published 2 August, 2022 pp. 1061–1065  
**A Multiresource Event Model Developed to Increase Access to COVID-19 Vaccines in Pima County, Arizona, Summer 2021**  
Amanda Monroy MA, Theresa Cullen MD, MS

*Brief Report*  First published 16 September, 2022 pp. 1066–1069  
**Availability of and Obstacles to Providing COVID-19 Vaccinations at Syringe Services Programs in the United States, 2021**  
Don C. Des Jarlais PhD

*Open Access  Research article*  First published 2 August, 2022 pp. 1162–1169  
**Parental COVID-19 Vaccine Hesitancy in the United States**  
Jeanette B. Ruiz PhD, Robert A. Bell PhD

*Open Access  Research article*  First published 2 August, 2022 pp. 1162–1169  
**Parental COVID-19 Vaccine Hesitancy in the United States**  
Jeanette B. Ruiz PhD, Robert A. Bell PhD

**Qualitative Health Research**
Volume 32 Issue 13, November 2022  
https://journals.sagepub.com/toc/qhra/current  
[Reviewed earlier]
Research Ethics
Volume 18 Issue 4, October 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 19 Nov 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
18 Nov 2022
Risk factors for intensive care unit admission and death from COVID-19 in fully vaccinated patients hospitalized for severe COVID-19, Brazil, 2021–2022
Original research | English |

18 Nov 2022
Risk factors for intensive care unit admission and death from COVID-19 in fully vaccinated patients hospitalized for severe COVID-19, Brazil, 2021–2022
Original research | English |

16 Nov 2022
Long-term respiratory outcomes after COVID-19: a Brazilian cohort study
Original research | English |

16 Nov 2022
Four reasons for adopting a life course approach to health in the COVID-19 era and beyond
Opinion and analysis | English |

Risk Analysis
Volume 42, Issue 10 Pages: 2125-2343 October 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Original Research Articles
Comparative Risk: Dread and Unknown Characteristics of the COVID-19 Pandemic Versus COVID-19 Vaccines
Jody Chin Sing Wong, Janet Zheng Yang
Pages: 2214-2230
First Published: 17 November 2021

Risk Management and Healthcare Policy
Science
Volume 378| Issue 6621| 18 Nov 2022
https://www.science.org/toc/science/current
Special issue: 75 years of transistors
Perspectives
COVID-19 vaccination and menstruation
BY Victoria Male
17 Nov 2022: 704-706 Free
COVID-19 vaccination causes small changes to menstruation that quickly resolve

Policy Forum
Research under China’s personal information law
BY Xiaojie Li, Yali Cong, Ruishuang Liu
Abstract
The Personal Information Protection Law (PIPL) that came into effect in the Peoples Republic of China (PRC) in November 2021 is in line with many international standards because it was designed by referring to jurisdictions of other nations, especially the provisions of the European Union (EU) General Data Protection Regulation (GDPR). Thus, the fundamental principles of the PIPL—such as lawfulness, fairness, transparency, accuracy, and purpose limitation—are now broadly in line with the GDPR. However, China has not used “academic derogation” or “academic exemptions” as have been used in European nations, the United States, and Australia to reconcile the protection of personal data rights with scientific research freedom in data processing (1). We provide here a general overview of the effect of the PIPL on ongoing and future transnational scientific research through a legal analysis of its provisions, and we suggest feasible solutions for challenges brought by the PIPL to transnational scientific research

Science and Engineering Ethics
Volume 28, issue 6, December 2022
[New issue; No digest content identified]

Science Translational Medicine
Volume 14| Issue 671| 16 Nov 2022
https://www.science.org/toc/stm/current
Viewpoints
The RTS,S malaria vaccine: Current impact and foundation for the future
BY James G. Beeson, et al.
16 Nov 2022
The RTS,S malaria vaccine is a new starting point for combating malaria and is a foundation for future vaccines.
Social Science & Medicine
Volume 313  November 2022
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 19 Nov 2022]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 43, issue 2-3, June 2022
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 50  November–December 2022
[Reviewed earlier]

Tropical Medicine & International Health
Volume 27, Issue 10  Pages: i-iv, 841-940  October 2022
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 40, Issue 46  Pages 6567-6688 (2 November 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/46
Short communication  Full text access
Trends in HPV vaccine administration and HPV vaccine coverage in children by race/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California
Chun R. Chao, Lanfang Xu, Nancy Cannizzaro, David Bronstein, ... Erin E. Hahn
Pages 6575-6580

Research article  Open access
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan
Kei Nakashima, Kanzo Suzuki, Masahiro Aoshima, Mayumi Murabata, ... Yoshio Hirota
Pages 6589-6598
Research article   Abstract only
**Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates**
Elizabeth Marlowe, Sarah Pranikoff, Briana Borsheim, Kiarash Salafian, ... David E. Kram
Pages 6625-6630

Research article   Abstract only
**Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis**
A.N.M. Kraay, M.K. Steele, J.M. Baker, E.W. Hall, ... B.A. Lopman
Pages 6631-6639

Research article   Open access
**An intersectional analysis of sociodemographic disparities in Covid-19 vaccination: A nationwide register-based study in Sweden**
M. Spetz, L. Lundberg, C. Nwaru, H. Li, ... M. Rosvall
Pages 6640-6648

Research article   Abstract only
**Shades of doubt: Measuring and classifying vaccination confidence in Europe**
Cosima Rughiniș, Simona-Nicoleta Vulpe, Michael G. Flaherty, Sorina Vasile
Pages 6670-6679

Research article   Full text access
**COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout**
Alexandra Byrne, Lindsay A. Thompson, Stephanie L. Filipp, Kathleen Ryan
Pages 6680-6687

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 19 Nov 2022]

Latest Articles
Open Access  Review
**COVID-19 Vaccination in Migrants and Refugees: Lessons Learnt and Good Practices**
by Palmira Immordino, et al.
Vaccines 2022, 10(11), 1965; https://doi.org/10.3390/vaccines10111965 (registering DOI) - 19 Nov 2022

Abstract
The COVID-19 pandemic has exacerbated inequalities between low- and high-income countries. Within the latter, a greater impact is seen in the poorest and most vulnerable people, including refugees, asylum seekers, and migrants. They all may experience poor access to quality healthcare or have

Open Access  Article
**Parents' Attitudes toward Childhood Vaccines and COVID-19 Vaccines in a Turkish Pediatric Outpatient Population**
by Nihal Durmaz, et al.
Vaccination hesitancy (VH) is an important public health issue. The determinants of parental decisions on whether to vaccinate their children are multidimensional and need to be carefully considered in the COVID-19 era. Our study aims to investigate the prevalence of VH among parents, [...] Read more.

Protecting the Offspring, the Gift of Maternal Immunization: Current Status and Future Perspectives
by Theano Lagousi, et al.
Abstract
Pregnancy is characterized by immunological alterations in pregnant women that permit the growth of a semi-allogenic fetus, resulting in greater susceptibility of childbearing women to infections. Furthermore, due to the immaturity of the immune system of neonates, a protection gap is present in [...] Read more.

COVID-19 Vaccination Hesitancy in Mexico City among Healthy Adults and Adults with Chronic Diseases: A Survey of Complacency, Confidence, and Convenience Challenges in the Transition to Endemic Control
by Miguel Ángel González-Block, et al.
Abstract
Background. Monitoring of SARS-COV-2 vaccine hesitancy is important for epidemic control. We measured vaccine hesitancy among healthy adults and adults with chronic diseases after they had been offered the first dose of the vaccine in Mexico City. Methods. An observational cross-sectional study was [...] Read more.

A Systematic Review on Vaccine hesitancy in Black Communities in Canada: Critical Issues and Research Failures
by Jude Mary Cénat, et al.
Abstract
Black communities have been disproportionately impacted by Coronavirus Disease 2019 (COVID-19) in Canada, in terms of both number of infections and mortality rates. Yet, according to early studies, vaccine hesitancy appears to be higher in Black communities. The purpose of this systematic review

Persisting Vaccine Hesitancy in Africa: The Whys, Global Public Health Consequences and Ways-Out—COVID-19 Vaccination Acceptance Rates as Case-in-Point
by Emmanuel O. Njoga, et al.
Abstract
Vaccine hesitancy (VH) is the seventh among the WHO’s top 10 threats to global public health, which has continued to perpetuate the transmission of vaccine preventable diseases (VPDs) in Africa.
Consequently, this paper systematically reviewed COVID-19 vaccine acceptance rates (VARs)—including the vaccine uptake

**Value in Health**  
December 2022 Volume 25 Issue 12 p1925-2080  
https://www.valueinhealthjournal.com/current  
[Reviewed earlier]

---

**Pre-Print Servers**

**Gates Open Research**  
https://gatesopenresearch.org/browse/articles  
Selected Research  
No new digest content identified.

**medRxiv**  
https://www.medrxiv.org/content/about-medrxiv  
[Filter: All articles]  
Selected Research  
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters  
Maria Rescigno, Chiara Agrati, Carlo Salvarani, Diana Giannarelli, Massimo Costantini, Alberto Mantovani, Raffaella Massafra, Pier Luigi Zinzani, Aldo Morrone, Stefania Notari, Giulia Matusali, Giuseppe Lauria Pinter, Antonio Uccelli, Gennaro Ciliberto, Fausto Baldanti, Franco Locatelli, Nicola Silvestris, Valentina Sinno, Elena Turola, VAX4FRAIL study Group, Maria Teresa Lupo Stanghellini, Giovanni Apolone  
medRxiv 2022.11.19.22282537; doi: https://doi.org/10.1101/2022.11.19.22282537

Frameworks for measuring population health: a scoping review  
Sze Ling Chan, Clement Zhong Hao Ho, Nang Ei Ei Khaing, Ezra Ho, Candelyn Pong, Calida Chua, Zongbin Li, Trudi Lim, Sean Shao Wei Lam, Lian Leng Low, Choon How How  
medRxiv 2022.11.17.22282470; doi: https://doi.org/10.1101/2022.11.17.22282470

Special Olympics global report on COVID-19 vaccination and reasons not to vaccinate among adults with intellectual disabilities
Andrew Ethan Lincoln, Alicia M Dixon-Ibarra, John P Hanley, Ashlyn L Smith, Kiki Martin, Alicia Bazzano
medRxiv 2022.11.16.22282406; doi: https://doi.org/10.1101/2022.11.16.22282406

**Estimating the impact of COVID-19 vaccine allocation inequities: a modeling study**
Nicolo Gozzi, Matteo Chinazzi, Natalie E Dean, Ira M Longini Jr., Elizabeth M Halloran, Nicola Perra, Alessandro Vespignani
medRxiv 2022.11.18.22228514; doi: https://doi.org/10.1101/2022.11.18.22228514

**Social Media Sensors to Detect Early Warnings of Influenza at Scale**
David Martin-Corral, Esteban Moro, Manuel Cebrian, Manuel Garcia-Herranz
medRxiv 2022.11.15.22228355; doi: https://doi.org/10.1101/2022.11.15.22228355

**Observational methods for COVID-19 vaccine effectiveness research: a trial emulation and empirical evaluation**
Martí Català, Edward Burn, Trishna Rathod-Mistry, Junqing Xie, Antonella Delmestri, Daniel Prieto-Alhambra, Annika M. Jödicke
medRxiv 2022.11.09.222282065; doi: https://doi.org/10.1101/2022.11.09.222282065

**A review of reviews exploring patient and public involvement in population health research**
Soo Vinnicombe, Jane Noyes
medRxiv 2022.11.16.222282319; doi: https://doi.org/10.1101/2022.11.16.222282319

**Transparency in infectious disease research: a meta-research survey of specialty journals**
Emmanuel A. Zavalis, Despina G. Contopoulos-Ioannidis, John P.A. Ioannidis
medRxiv 2022.11.12.222282231; doi: https://doi.org/10.1101/2022.11.12.222282231

**OSF Pre-prints**
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 19 Nov 2022]
[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

**Evidence from 35 countries that the social perception of key protagonists is associated with containment measures during the COVID-19 pandemic**
Maria-Therese Friehs
Patrick Kotzur
Christine Kraus
Moritz Schemmerling
Jessica Alina Herzig
Adrian Stanciu
Sebastian Dilly
Lisa Hellert
Doreen Hübner
Anja Rückwardt +56
Last edited: Nov 17, 2022 UTC
Social and Behavioral Sciences Psychology Social Psychology

It is crucial to understand why people comply with measures to contain viruses and their effects during pandemics. We provide evidence from 35 countries (Ntotal = 12,553) from six continents during
the COVID-19 pandemic that the social perception of key protagonists on two basic dimensions of social ...
OSF Preprints

**Wellcome Open Research** [to 19 Nov 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 19 Nov 2022]

*Selected Research*

*Systematic Review* metrics

*Update*

**A living mapping review for COVID-19 funded research projects: 21 month update** [version 8; peer review: 2 approved]
Adrian Bucher, Emilia Antonio, Henrike Grund, Nusrat Jabin, Chantel Jones, Meron Kifle, Susan Khader, Genevieve Boily-Larouche, Morgan Lay, Alice Norton
Peer Reviewers David Vaughn; Peter Smith

*Funders*
Wellcome Trust
European Commission
UK Research and Innovation
Department of Health, Social Services and Public Safety, UK Government

**LATEST VERSION PUBLISHED** 16 Nov 2022

*Study Protocol* metrics AWAITING PEER REVIEW

**The PRECISE-DYAD protocol: linking maternal and infant health trajectories in sub-Saharan Africa** [version 1; peer review: awaiting peer review]
Rachel Craik, Marie-Laure Volvert, Angela Koech, Hawanatu Jah, Kelly Pickerill, Amina Abubakar, Umberto D’Alessandro, Benjamin Barratt, Hannah Blencowe, Jeffrey N Bone, Jaya Chandna, Melissa Gladstone, Asma Khalil, Larry Li, Laura A Magee, Liberty Makacha, Hiten D Mistry, Sophie Moore, Anna Roca, Tatiana T Salisbury, Marleen Temmerman, Danielle Toudup, Marianne Vidler, Peter von Dadelszen, and The PRECISE-DYAD Network
Peer Reviewers Invited
Funders
Wellcome Trust
United Kingdom Research and Innovation GCRF GROW award

**PUBLISHED** 14 Nov 2022

* * * *

**Think Tanks**

**Brookings** [to 19 Nov 2022]
http://www.brookings.edu/

*Latest Research [Selected]*
No new digest content identified
Center for Global Development  [to 19 Nov 2022]
https://www.cgdev.org/
All Research [Selected]
POLICY PAPERS
An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment
Rachel Silverman and Adrian Towse
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant inf...
Latest Publications
No new digest content identified.

Rand  [to 19 Nov 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
Journal Article
The Equity-First Vaccination Initiative’s Challenges And Successes
  RAND collected, analyzed, and co-interpreted with other Equity-First Vaccination Initiative (EVI) partners both quantitative and qualitative data to promote equity in the COVID-19 response through vaccination.
Nov 17, 2022
Laura J. Faherty, Sarah Hanck, Nichelle Walton, George Timmins, Gregory Johnson, Jeanne S. Ringel

Journal Article
Association of COVID-19 Vaccination With Influenza Vaccine History and Changes in Influenza Vaccination
  Using the RAND American Life Panel (ALP), we examine relationships among COVID and influenza vaccination amongst those who historically never, sometimes, or always vaccinate for influenza.
Nov 16, 2022
Andrew M. Parker, Samer Atshan, Matthew Walsh, Courtney A. Gidengil, Raffaele Vardavas

Urban Institute  [to 19 Nov 2022]
https://www.urban.org/publications
New Research Publications
No new digest content identified.

World Economic Forum  [to 19 Nov 2022]
https://agenda.weforum.org/news/
Media
No new digest content identified.

* * * *
* * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.
CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.